Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IPSEY
CUSIPN/A
Phone33-01-58-33-50-00
Debt
Debt-to-Equity RatioN/A
Current Ratio1.08
Quick Ratio0.90
Price-To-Earnings
Trailing P/E Ratio44.87
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.27 billion
Price / Sales6.15
Cash Flow$1.2777 per share
Price / Cash32.66
Book Value$5.19 per share
Price / Book8.04
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees4,907
Outstanding Shares334,770,000
Market Cap$13,973.22
IPSEN S A/S (OTCMKTS:IPSEY) Frequently Asked Questions
What is IPSEN S A/S's stock symbol?
IPSEN S A/S trades on the OTCMKTS under the ticker symbol "IPSEY."
What is the consensus analysts' recommendation for IPSEN S A/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IPSEN S A/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of IPSEN S A/S's key competitors?
Some companies that are related to IPSEN S A/S include IDEXX Laboratories (IDXX), Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT) and Vermillion (VRML).
Who are IPSEN S A/S's key executives?
IPSEN S A/S's management team includes the folowing people:
- Mr. David D. Meek, CEO & Director (Age 55)
- Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 49)
- Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 52)
- Dr. Alexandre P. Lebeaut, Exec. VP of R&D and Chief Scientific Officer (Age 61)
- Ms. Eugenia Litz, VP of Investor Relations
Has IPSEN S A/S been receiving favorable news coverage?
Media stories about IPSEY stock have trended positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. IPSEN S A/S earned a news sentiment score of 0.29 on Accern's scale. They also gave media headlines about the company an impact score of 46.29 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of IPSEN S A/S?
Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IPSEN S A/S's stock price today?
One share of IPSEY stock can currently be purchased for approximately $41.73.
How big of a company is IPSEN S A/S?
IPSEN S A/S has a market capitalization of $13.97 billion and generates $2.27 billion in revenue each year. The company earns $307.78 million in net income (profit) each year or $0.93 on an earnings per share basis. IPSEN S A/S employs 4,907 workers across the globe.
How can I contact IPSEN S A/S?
IPSEN S A/S's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]
MarketBeat Community Rating for IPSEN S A/S (OTCMKTS IPSEY)
MarketBeat's community ratings are surveys of what our community members think about IPSEN S A/S and other stocks. Vote "Outperform" if you believe IPSEY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPSEY will underperform the S&P 500 over the long term. You may vote once every thirty days.
